136 related articles for article (PubMed ID: 27583403)
1. Neuraminidase Inhibitors and Hospital Mortality in British Patients with H1N1 Influenza A: A Re-Analysis of Observational Data.
Wolkewitz M; Schumacher M
PLoS One; 2016; 11(9):e0160430. PubMed ID: 27583403
[TBL] [Abstract][Full Text] [Related]
2. Survival biases lead to flawed conclusions in observational treatment studies of influenza patients.
Wolkewitz M; Schumacher M
J Clin Epidemiol; 2017 Apr; 84():121-129. PubMed ID: 28188897
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data.
Muthuri SG; Venkatesan S; Myles PR; Leonardi-Bee J; Al Khuwaitir TS; Al Mamun A; Anovadiya AP; Azziz-Baumgartner E; Báez C; Bassetti M; Beovic B; Bertisch B; Bonmarin I; Booy R; Borja-Aburto VH; Burgmann H; Cao B; Carratala J; Denholm JT; Dominguez SR; Duarte PA; Dubnov-Raz G; Echavarria M; Fanella S; Gao Z; Gérardin P; Giannella M; Gubbels S; Herberg J; Iglesias AL; Hoger PH; Hu X; Islam QT; Jiménez MF; Kandeel A; Keijzers G; Khalili H; Knight M; Kudo K; Kusznierz G; Kuzman I; Kwan AM; Amine IL; Langenegger E; Lankarani KB; Leo YS; Linko R; Liu P; Madanat F; Mayo-Montero E; McGeer A; Memish Z; Metan G; Mickiene A; Mikić D; Mohn KG; Moradi A; Nymadawa P; Oliva ME; Ozkan M; Parekh D; Paul M; Polack FP; Rath BA; Rodríguez AH; Sarrouf EB; Seale AC; Sertogullarindan B; Siqueira MM; Skręt-Magierło J; Stephan F; Talarek E; Tang JW; To KK; Torres A; Törün SH; Tran D; Uyeki TM; Van Zwol A; Vaudry W; Vidmar T; Yokota RT; Zarogoulidis P; ; Nguyen-Van-Tam JS
Lancet Respir Med; 2014 May; 2(5):395-404. PubMed ID: 24815805
[TBL] [Abstract][Full Text] [Related]
4. Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection.
Venkatesan S; Myles PR; Bolton KJ; Muthuri SG; Al Khuwaitir T; Anovadiya AP; Azziz-Baumgartner E; Bajjou T; Bassetti M; Beovic B; Bertisch B; Bonmarin I; Booy R; Borja-Aburto VH; Burgmann H; Cao B; Carratala J; Chinbayar T; Cilloniz C; Denholm JT; Dominguez SR; Duarte PAD; Dubnov-Raz G; Fanella S; Gao Z; Gérardin P; Giannella M; Gubbels S; Herberg J; Higuera Iglesias AL; Hoeger PH; Hu XY; Islam QT; Jiménez MF; Keijzers G; Khalili H; Kusznierz G; Kuzman I; Langenegger E; Lankarani KB; Leo YS; Libster RP; Linko R; Madanat F; Maltezos E; Mamun A; Manabe T; Metan G; Mickiene A; Mikić D; Mohn KGI; Oliva ME; Ozkan M; Parekh D; Paul M; Rath BA; Refaey S; Rodríguez AH; Sertogullarindan B; Skręt-Magierło J; Somer A; Talarek E; Tang JW; To K; Tran D; Uyeki TM; Vaudry W; Vidmar T; Zarogoulidis P; ; Nguyen-Van-Tam JS
J Infect Dis; 2020 Jan; 221(3):356-366. PubMed ID: 31314899
[TBL] [Abstract][Full Text] [Related]
5. Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an individual participant data meta-analysis.
Muthuri SG; Venkatesan S; Myles PR; Leonardi-Bee J; Lim WS; Al Mamun A; Anovadiya AP; Araújo WN; Azziz-Baumgartner E; Báez C; Bantar C; Barhoush MM; Bassetti M; Beovic B; Bingisser R; Bonmarin I; Borja-Aburto VH; Cao B; Carratala J; Cuezzo MR; Denholm JT; Dominguez SR; Duarte PA; Dubnov-Raz G; Echavarria M; Fanella S; Fraser J; Gao Z; Gérardin P; Giannella M; Gubbels S; Herberg J; Higuera Iglesias AL; Hoeger PH; Hoffmann M; Hu X; Islam QT; Jiménez MF; Kandeel A; Keijzers G; Khalili H; Khandaker G; Knight M; Kusznierz G; Kuzman I; Kwan AM; Lahlou Amine I; Langenegger E; Lankarani KB; Leo YS; Linko R; Liu P; Madanat F; Manabe T; Mayo-Montero E; McGeer A; Memish ZA; Metan G; Mikić D; Mohn KG; Moradi A; Nymadawa P; Ozbay B; Ozkan M; Parekh D; Paul M; Poeppl W; Polack FP; Rath BA; Rodríguez AH; Siqueira MM; Skręt-Magierło J; Talarek E; Tang JW; Torres A; Törün SH; Tran D; Uyeki TM; van Zwol A; Vaudry W; Velyvyte D; Vidmar T; Zarogoulidis P; ; Nguyen-Van-Tam JS
Influenza Other Respir Viruses; 2016 May; 10(3):192-204. PubMed ID: 26602067
[TBL] [Abstract][Full Text] [Related]
6. Use of neuraminidase inhibitors in primary health care during pandemic and seasonal influenza between 2009 and 2013.
Blanchon T; Geffrier F; Turbelin C; Daviaud I; Laouénan C; Duval X; Lambert B; Hanslik T; Mosnier A; Leport C
Antivir Ther; 2015; 20(7):753-61. PubMed ID: 25687219
[TBL] [Abstract][Full Text] [Related]
7. Impact of Outpatient Neuraminidase Inhibitor Treatment in Patients Infected With Influenza A(H1N1)pdm09 at High Risk of Hospitalization: An Individual Participant Data Metaanalysis.
Venkatesan S; Myles PR; Leonardi-Bee J; Muthuri SG; Al Masri M; Andrews N; Bantar C; Dubnov-Raz G; Gérardin P; Koay ESC; Loh TP; Memish Z; Miller E; Oliva ME; Rath BA; Schweiger B; Tang JW; Tran D; Vidmar T; Waight PA; Nguyen-Van-Tam JS
Clin Infect Dis; 2017 May; 64(10):1328-1334. PubMed ID: 28199524
[TBL] [Abstract][Full Text] [Related]
8. Neuraminidase inhibitors were widely used in the UK during the 2009 influenza A(H1N1) pandemic.
Nguyen-Van-Tam JS; Nicholson KG
J Clin Virol; 2011 Feb; 50(2):183. PubMed ID: 21112812
[No Abstract] [Full Text] [Related]
9. Prognosis of hospitalized patients with 2009 H1N1 influenza in Spain: influence of neuraminidase inhibitors.
Delgado-Rodríguez M; Castilla J; Godoy P; Martín V; Soldevila N; Alonso J; Astray J; Baricot M; Cantón R; Castro A; Gónzález-Candelas F; Mayoral JM; Quintana JM; Pumarola T; Tamames S; Sáez M; Domínguez A;
J Antimicrob Chemother; 2012 Jul; 67(7):1739-45. PubMed ID: 22467633
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of neuraminidase inhibitors in preventing hospitalization during the H1N1 influenza pandemic in British Columbia, Canada.
Marra F; Chong M; Henry B; Patrick DM; Kendall P
J Antimicrob Chemother; 2014 May; 69(5):1397-406. PubMed ID: 24346762
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the clinical symptoms and the effectiveness of neuraminidase inhibitors for patients with pandemic influenza H1N1 2009 or seasonal H1N1 influenza in the 2007-2008 and 2008-2009 seasons.
Kawai N; Ikematsu H; Tanaka O; Matsuura S; Maeda T; Yamauchi S; Hirotsu N; Nishimura M; Iwaki N; Kashiwagi S
J Infect Chemother; 2011 Jun; 17(3):375-81. PubMed ID: 21120678
[TBL] [Abstract][Full Text] [Related]
12. Comparison between virus shedding and fever duration after treating children with pandemic A H1N1/09 and children with A H3N2 with a neuraminidase inhibitor.
Sugaya N; Sakai-Tagawa Y; Bamba M; Yasuhara R; Yamazaki M; Kawakami C; Yamaguchi Y; Ide Y; Ichikawa M; Mitamura K; Kawaoka Y
Antivir Ther; 2015; 20(1):49-55. PubMed ID: 24832015
[TBL] [Abstract][Full Text] [Related]
13. [Neuraminidase inhibitors - lessons from the swine flu].
Markun S
Praxis (Bern 1994); 2013 May; 102(11):687-8. PubMed ID: 23692909
[No Abstract] [Full Text] [Related]
14. The beneficial effects of neuraminidase inhibitor drug therapy on severe patient outcomes during the 2009-2010 influenza A virus subtype H1N1 pandemic.
Aoki FY; Hayden FG
J Infect Dis; 2013 Feb; 207(4):547-9. PubMed ID: 23204176
[No Abstract] [Full Text] [Related]
15. Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients.
Muthuri SG; Myles PR; Venkatesan S; Leonardi-Bee J; Nguyen-Van-Tam JS
J Infect Dis; 2013 Feb; 207(4):553-63. PubMed ID: 23204175
[TBL] [Abstract][Full Text] [Related]
16. Oseltamivir boosts 2009 H1N1 virus infectivity in vitro.
Lin X; Zhou J; Zhang Y; Wu J; Zhang F; Li Z; Zhang Y; Bi S; Shu Y; Wang Y
Biochem Biophys Res Commun; 2009 Dec; 390(4):1305-8. PubMed ID: 19879239
[TBL] [Abstract][Full Text] [Related]
17. Safety and effectiveness of neuraminidase inhibitors in situations of pandemic and/or novel/variant influenza: a systematic review of the literature, 2009-15.
Boikos C; Caya C; Doll MK; Kraicer-Melamed H; Dolph M; Delisle G; Winters N; Gore G; Quach C
J Antimicrob Chemother; 2017 Jun; 72(6):1556-1573. PubMed ID: 28204554
[TBL] [Abstract][Full Text] [Related]
18. Clinical effectiveness of neuraminidase inhibitors--oseltamivir, zanamivir, laninamivir, and peramivir--for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan.
Shobugawa Y; Saito R; Sato I; Kawashima T; Dapat C; Dapat IC; Kondo H; Suzuki Y; Saito K; Suzuki H
J Infect Chemother; 2012 Dec; 18(6):858-64. PubMed ID: 22644080
[TBL] [Abstract][Full Text] [Related]
19. Very low pandemic influenza A (H1N1) 2009 mortality associated with early neuraminidase inhibitor treatment in Japan: analysis of 1000 hospitalized children.
Sugaya N; Shinjoh M; Mitamura K; Takahashi T
J Infect; 2011 Oct; 63(4):288-94. PubMed ID: 21722665
[TBL] [Abstract][Full Text] [Related]
20. Timing of oseltamivir administration and outcomes in hospitalized adults with pandemic 2009 influenza A(H1N1) virus infection.
Viasus D; Paño-Pardo JR; Pachón J; Riera M; López-Medrano F; Payeras A; Fariñas MC; Moreno A; Rodríguez-Baño J; Oteo JA; Ortega L; Torre-Cisneros J; Segura F; Carratalà J;
Chest; 2011 Oct; 140(4):1025-1032. PubMed ID: 21415133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
